ArticleFrontiers in oncology2026
tsRNA-Ala-3-0030 drives ovarian cancer progression by suppressing ZNF70.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, ovarian cancer remains a leading cause of gynecologic cancer death. This poor prognosis is primarily attributed to advanced disease at diagnosis, a high propensity for recurrence, and the inadequate therapeutic efficacy of current standard regimens. Emerging evidence has established the functional significance of transfer RNA-derived small RNAs (tsRNAs) in tumor biology. Nevertheless, their exact mechanisms and roles in ovarian cancer pathogenesis are not yet fully understood. Our research was designed to profile tsRNA expression, verify its presence in ovarian cancer tissues and established cell lines, and leverage cellular and animal models to decipher the functional roles and molecular mechanisms of these molecules. Our analysis revealed that tsRNA-Ala-3-0030 is significantly upregulated in ovarian cancer models. Higher expression levels of this tsRNA were associated with enhanced malignant behaviors, including proliferation, migration, and invasion. The suppression of tsRNA-Ala-3-0030 expression attenuated these malignant phenotypes, whereas its overexpression promoted tumor progression in both cellular cultures and xenograft models. Mechanistically, tsRNA-Ala-3-0030 directly targeted the tumor suppressor ZNF70, leading to its downregulation and consequent promotion of ovarian cancer growth and metastasis. Restoration of ZNF70 expression reversed the oncogenic effects of tsRNA-Ala-3-0030, confirming its pivotal role in mediating this pathway. Collectively, our findings reveal tsRNA-Ala-3-0030 as a previously unrecognized oncogenic regulator that promotes ovarian cancer progression through ZNF70 downregulation. This study elucidates a tsRNA-dependent tumorigenic mechanism and positions tsRNA-Ala-3-0030 as a dual-purpose prognostic indicator and therapeutic target, advancing personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.